Literature DB >> 10697021

Pharmacological management of cancer pain.

D Walsh1.   

Abstract

Given modern techniques of pain assessment and management, it is now possible to be optimistic about cancer pain control. Assessment of cancer pain must include information about the site(s) of pain, pathophysiology, pain severity, and quantification of analgesic responses. Correct diagnosis of common pain patterns including breakthrough and incident pain are essential. The principles of analgesic use are well defined. The concept of rescue dosing in safe analgesic titration and management of breakthrough/incident pain is a key concept. Individualization of opioid dosing is important and this is facilitated by a number of dosing strategies. Choice of specific opioid is often less important than correct dosing, as side effects are similar among the commonly prescribed drugs. Anticipations and management of common side effects improve the therapeutic index. Alternate routes of administration are important, usually because of loss of the oral route of administration. Misunderstandings about opioids are common and patient and family education paramount. Adjuvant analgesics are necessary for good pain control, but have important differences in indications, usage, and side effects compared with opioids. First-rate pain management is a basic professional and humanitarian responsibility of the skilled clinical oncologist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697021

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  11 in total

1.  Chronic pain and narcotics: a dilemma for primary care.

Authors:  Yngvild Olsen; Gail L Daumit
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 2.  Advances in opioid therapy and formulations.

Authors:  Declan Walsh
Journal:  Support Care Cancer       Date:  2004-12-14       Impact factor: 3.603

3.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

4.  Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

Authors:  Daniel D Long; Scott R Armstrong; David T Beattie; Christina B Campbell; Timothy J Church; Pierre-Jean Colson; Sean M Dalziel; John R Jacobsen; Lan Jiang; Glenmar P Obedencio; Miroslav Rapta; Daisuke Saito; Ioanna Stergiades; Pamela R Tsuruda; Priscilla M Van Dyke; Ross G Vickery
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

Review 5.  Ethical Tensions in the Pain Management of an End-Stage Cancer Patient with Evidence of Opioid Medication Diversion.

Authors:  Arvind Venkat; David Kim
Journal:  HEC Forum       Date:  2016-06

6.  The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014.

Authors:  Kathryn R Tringale; Minh-Phuong Huynh-Le; Mia Salans; Deborah C Marshall; Yuyan Shi; Jona A Hattangadi-Gluth
Journal:  Cancer       Date:  2019-04-22       Impact factor: 6.860

7.  Intermittent cancer pain: clinical importance and an updated cancer pain classification.

Authors:  Wael Lasheen; Declan Walsh; Nabeel Sarhill; Mellar Davis
Journal:  Am J Hosp Palliat Care       Date:  2009-12-14       Impact factor: 2.500

Review 8.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.

Authors:  D T Beattie; M Cheruvu; N Mai; M O'Keefe; S Johnson-Rabidoux; C Peterson; E Kaufman; R Vickery
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-06       Impact factor: 3.000

10.  Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.

Authors:  Rakesh H Vekariya; Wei Lei; Abhisek Ray; Surendra K Saini; Sixue Zhang; Gabriella Molnar; Deborah Barlow; Kelly L Karlage; Edward J Bilsky; Karen L Houseknecht; Tally M Largent-Milnes; John M Streicher; Subramaniam Ananthan
Journal:  J Med Chem       Date:  2020-06-30       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.